Advertisement
UK markets close in 4 hours 8 minutes

  • FTSE 100

    8,119.04
    +40.18 (+0.50%)
     

  • FTSE 250

    19,815.99
    +214.01 (+1.09%)
     

  • AIM

    755.44
    +2.32 (+0.31%)
     

  • GBP/EUR

    1.1661
    +0.0005 (+0.04%)
     

  • GBP/USD

    1.2517
    +0.0006 (+0.05%)
     

  • Bitcoin GBP

    51,298.54
    +379.71 (+0.75%)
     

  • CMC Crypto 200

    1,383.78
    -12.75 (-0.91%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.11
    +0.54 (+0.65%)
     

  • GOLD FUTURES

    2,359.40
    +16.90 (+0.72%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,061.57
    +144.29 (+0.81%)
     

  • CAC 40

    8,044.98
    +28.33 (+0.35%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Was This Acquisition a Savvy Play by This Big Pharma Stock?

Kody Kester, The Motley Fool
·3-min read
Was This Acquisition a Savvy Play by This Big Pharma Stock?

Earlier this month, U.K.-based drugmaker GSK (NYSE: GSK) reached a deal to buy Canadian biotech company Bellus Health (NASDAQ: BLU) for $2 billion in cash. Should GSK's deal for Bellus Health be approved by regulatory authorities and a two-thirds majority of the latter's shareholders, the former will pick up a promising drug candidate, camlipixant, that aims to treat refractory chronic cough (RCC). Surprisingly, there are no approved therapies for RCC in the United States or the European Union.

Continue reading